Clinical characteristics
| Characteristic . | Value, n (%) . |
|---|---|
| Median age (range), y | 59 (19-69) |
| Female | 10 (29) |
| Median time post-allo-HSCT (range), mo | 35 (24-42) |
| Disease | |
| AML/MDS-EB2 | 13 (37) |
| ALL | 4 (11) |
| CML | 2 (6) |
| MM | 5 (14) |
| NHL | 1 (3) |
| MPN | 4 (11) |
| CMML | 2 (6) |
| MDS* | 4 (11) |
| Donor type | |
| MRD | 4 (11) |
| MUD (10/10) | 21 (60) |
| MMUD (9/10) | 10 (29) |
| DLI (1 × 105 CD3 cells per kg) | 19 (54) |
| Median time to DLI (range), wk | 11 (7-16) |
| CMV recipient/donor | |
| +/+ | 9 (26) |
| +/− | 8 (23) |
| −/+ | 4 (11) |
| −/− | 14 (40) |
| EBV recipient/donor | |
| +/+ | 23 (66) |
| +/− | 4 (11) |
| −/+ | 4 (11) |
| −/− | 0 (0) |
| +/unknown | 4 (11) |
| Characteristic . | Value, n (%) . |
|---|---|
| Median age (range), y | 59 (19-69) |
| Female | 10 (29) |
| Median time post-allo-HSCT (range), mo | 35 (24-42) |
| Disease | |
| AML/MDS-EB2 | 13 (37) |
| ALL | 4 (11) |
| CML | 2 (6) |
| MM | 5 (14) |
| NHL | 1 (3) |
| MPN | 4 (11) |
| CMML | 2 (6) |
| MDS* | 4 (11) |
| Donor type | |
| MRD | 4 (11) |
| MUD (10/10) | 21 (60) |
| MMUD (9/10) | 10 (29) |
| DLI (1 × 105 CD3 cells per kg) | 19 (54) |
| Median time to DLI (range), wk | 11 (7-16) |
| CMV recipient/donor | |
| +/+ | 9 (26) |
| +/− | 8 (23) |
| −/+ | 4 (11) |
| −/− | 14 (40) |
| EBV recipient/donor | |
| +/+ | 23 (66) |
| +/− | 4 (11) |
| −/+ | 4 (11) |
| −/− | 0 (0) |
| +/unknown | 4 (11) |
CML, chronic myeloid lymphoma; CMML, chronic myelomonocytic leukemia; MDS-EB2, myelodysplastic syndrome with excess of blasts-2; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma.
*Indicates all MDS except MDS-EB2.